Dual Pricing Of Patented Drugs Not Workable, Say Indian Generic Drug Makers
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Indian drug makers seem headed for collision with the government's moves to effect a dual pricing mechanism of patented drugs imported by multinational drug companies. Of late, the government has accelerated efforts to arrive at a consensus between Indian and multinational companies as well as non-government organizations for making patented drugs available at an affordable cost to the poorer sections of the Indian population